AEVI-001: Ph I/II started
Aevi began an open-label, U.S. Phase I/II trial evaluating 50, 100, 200 and 400 mg oral AEVI-001 twice daily over 5 weeks in about 12 patients ages 12-17 with a 22q11.2 deletion and diagnosed with anx...
BCIQ Company Profiles
BCIQ Target Profiles
Metabotropic glutamate receptor subtype 1 (mGluR1) (GRM1)
Metabotropic glutamate receptor subtype 3 (mGluR3) (GRM3)
Metabotropic glutamate receptor subtype 5 (mGluR5) (GRM5)
Metabotropic glutamate receptor subtype 7 (mGluR7) (GRM7)